GenScript

𝗟𝗲𝘀𝘀 𝘁𝗶𝗺𝗲 𝗺𝗮𝗻𝗮𝗴𝗶𝗻𝗴 𝗽𝘂𝗿𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻. 𝗠𝗼𝗿𝗲 𝘁𝗶𝗺𝗲 𝗳𝗼𝗿 𝘀𝗰𝗶𝗲𝗻𝗰𝗲. 𝗔𝗺𝗠𝗮𝗴™ 𝗤𝘂𝗮𝘁𝗿𝗼 brings walkaway automation to purification workflows, helping scientists spend less time on routine processing and more time moving research forward. Explore the Quatro portfolio to find the right instrument for your lab’s workflow and scale. 𝗙𝗶𝗻𝗱 𝘆𝗼𝘂𝗿 𝗤𝘂𝗮𝘁𝗿𝗼 → Then experience it with an 𝗶𝗻-𝗹𝗮𝗯 𝗱𝗲𝗺𝗼.

𝗜𝗻 𝘃𝗶𝘃𝗼 𝗖𝗔𝗥-𝗧 𝗶𝘀 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗱𝗮𝘁𝗮 𝗶𝘀 𝘄𝗼𝗿𝘁𝗵 𝗮 𝗰𝗹𝗼𝘀𝗲𝗿 𝗹𝗼𝗼𝗸. Join Mark Shulewitz, PhD, Field Application Scientist at GenScript, for the 𝘪𝘯 𝘷𝘪𝘷𝘰 CAR-T webinar exploring three key advances: 🔹𝗖𝗔𝗥 𝗰𝗼𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝘀, 𝗺𝗶𝗻𝘂𝘀 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆: modular “drop-in” CAR plasmids that simplify design and accelerate RNA production. 🔹𝗥𝗡𝗔 𝘄𝗶𝘁𝗵 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹: engineered RNA caps, modified poly(A) tails and selective UTRs designed to improve expression and specificity. 🔹𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝘁𝗵𝗮𝘁 𝗸𝗻𝗼𝘄𝘀 𝘄𝗵𝗲𝗿𝗲 𝘁𝗼 𝗴𝗼: spleen-tropic and VHH-conjugated LNPs for more targeted T-cell delivery, including preclinical evidence of tumor control with CAR circRNA. 📆 November 5, 2026 🕚 11 am EST | 4 pm GMT | 5 pm CET

𝗜𝗻 𝘃𝗶𝘃𝗼 𝗖𝗔𝗥-𝗧 𝗶𝘀 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗱𝗮𝘁𝗮 𝗶𝘀 𝘄𝗼𝗿𝘁𝗵 𝗮 𝗰𝗹𝗼𝘀𝗲𝗿 𝗹𝗼𝗼𝗸. Join Mark Shulewitz, PhD, Field Application Scientist at GenScript, for the 𝘪𝘯 𝘷𝘪𝘷𝘰 CAR-T webinar exploring three key advances: 🔹𝗖𝗔𝗥 𝗰𝗼𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝘀, 𝗺𝗶𝗻𝘂𝘀 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆: modular “drop-in” CAR plasmids that simplify design and accelerate RNA production. 🔹𝗥𝗡𝗔 𝘄𝗶𝘁𝗵 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹: engineered RNA caps, modified poly(A) tails and selective UTRs designed to improve expression and specificity. 🔹𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝘁𝗵𝗮𝘁 𝗸𝗻𝗼𝘄𝘀 𝘄𝗵𝗲𝗿𝗲 𝘁𝗼 𝗴𝗼: spleen-tropic and VHH-conjugated LNPs for more targeted T-cell delivery, including preclinical evidence of tumor control with CAR circRNA. 📆 November 5, 2026 🕚 11 am EST | 4 pm GMT | 5 pm CET

𝗠𝗼𝘀𝘁 𝗔𝗜 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸𝘀 𝘀𝘁𝗼𝗽 𝗮𝘁 𝗼𝗻𝗲 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻: Does it bind? But in real drug discovery, 𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝗶𝘀 𝗼𝗻𝗹𝘆 𝘁𝗵𝗲 𝗯𝗲𝗴𝗶𝗻𝗻𝗶𝗻𝗴. That's why GenScript and Geodesic are launching the 𝗕𝗲𝘆𝗼𝗻𝗱 𝗕𝗶𝗻𝗱𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲, a global competition designed to evaluate not just antibody binding, but the developability characteristics that matter for therapeutic success. → Design antibody candidates against a challenging target → Receive binding performance experimentally evaluated through GenScript’s Sequence-to-Data workflow → Refine and optimize their designs based on real-world results → Compete in a second round of validation and developability assessment If you're building AI for biologics discovery, this is your opportunity to benchmark your approach against the next frontier of protein design. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝘆𝗼𝘂𝗿 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁 𝗮𝗻𝗱 𝗯𝗲 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘁𝗼 𝗵𝗲𝗮𝗿 𝘄𝗵𝗲𝗻 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻.

𝗠𝗼𝘀𝘁 𝗔𝗜 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸𝘀 𝘀𝘁𝗼𝗽 𝗮𝘁 𝗼𝗻𝗲 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻: Does it bind? But in real drug discovery, 𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝗶𝘀 𝗼𝗻𝗹𝘆 𝘁𝗵𝗲 𝗯𝗲𝗴𝗶𝗻𝗻𝗶𝗻𝗴. That's why GenScript and Geodesic are launching the 𝗕𝗲𝘆𝗼𝗻𝗱 𝗕𝗶𝗻𝗱𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲, a global competition designed to evaluate not just antibody binding, but the developability characteristics that matter for therapeutic success. → Design antibody candidates against a challenging target → Receive binding performance experimentally evaluated through GenScript’s Sequence-to-Data workflow → Refine and optimize their designs based on real-world results → Compete in a second round of validation and developability assessment If you're building AI for biologics discovery, this is your opportunity to benchmark your approach against the next frontier of protein design. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝘆𝗼𝘂𝗿 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁 𝗮𝗻𝗱 𝗯𝗲 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘁𝗼 𝗵𝗲𝗮𝗿 𝘄𝗵𝗲𝗻 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻.

𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝘄𝗵𝗮𝘁 𝗰𝗼𝗺𝗲𝘀 𝗮𝗳𝘁𝗲𝗿 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗥𝗜𝗦𝗣𝗥/𝗖𝗮𝘀𝟵? Our new beginner’s guide breaks down how guide RNA has evolved to support advanced technologies including base editing, prime editing, PASSIGE, and retron-mediated editing. Read our new Beginner’s Guide to Guide RNA for Advanced Gene Editing to explore: 🧬 How CRISPR technologies have advanced beyond Cas9 🧬 How gRNA requirements differ across emerging editing systems 🧬 What to consider when moving into more complex applications 🧬 How extended-length gRNA can support next-generation workflows Download and explore your next gene editing workflow now.